TRVI
Trevi Therapeutics, Inc.12.41
-0.20-1.59%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Key Stats
Market Cap
1.59BP/E (TTM)
-Basic EPS (TTM)
-0.37Dividend Yield
0%Recent Filings
8-K
CFO Hastings hired
Trevi Therapeutics hired David Hastings as CFO effective January 6, 2026, announced December 4, 2025. The biopharma finance veteran, with stints at Arbutus, Incyte, and others, gets $522,000 base salary, 40% bonus potential, and options for 375,000 shares vesting over four years. Leadership bolsters financial oversight amid clinical pushes.
8-K
Trevi Q3 loss narrows, Phase 3 ahead
Trevi Therapeutics reported a Q3 2025 net loss of $11.8 million, improved from $13.2 million last year, while ending with $194.9 million in cash to fund operations into 2028. The company plans an End-of-Phase 2 FDA meeting in Q4 2025 and Phase 3 initiation for Haduvio in IPF chronic cough by H1 2026, following positive safety data from the TIDAL study and no issues in drug interaction trials with antifibrotics. Phase 2b results for IPF cough were presented at CHEST 2025. Cash supports pipeline advances.
10-Q
Q3 FY2025 results
Trevi Therapeutics narrowed its Q3 operating loss to $13.9M from $14.1M a year earlier, while net loss improved to $11.8M from $13.2M y/y, thanks to higher interest income of $2.1M offsetting R&D spend on Haduvio trials for chronic cough in IPF and RCC. YTD through September 30, 2025, operating expenses held steady at $39.1M versus $39.3M last year, with cash burn from operations at $34.5M cushioned by a June offering that boosted cash and equivalents to $56.9M plus $138.1M in marketable securities. Diluted EPS of -$0.08 reconciles cleanly to 145M weighted shares, no anti-dilution quirks. Liquidity looks solid, no debt burdens. Yet clinical trial delays could stretch the runway.
8-K
CFO resigns, CEO takes interim role
Trevi Therapeutics' CFO Lisa Delfini resigned effective August 22, 2025, with no disagreements over company matters; she'll receive separation benefits under the executive plan after signing a release. CEO Jennifer Good steps in as interim principal financial officer. This leadership shift maintains continuity amid ongoing operations.
10-Q
Q2 FY2025 results
Trevi Therapeutics narrowed its Q2 operating loss to $13.7M from $13.3M a year earlier, while YTD loss held steady at $25.2M despite steady R&D spend on Haduvio trials; diluted EPS improved to $(0.09) from $(0.12) y/y, reconciling cleanly with 130M weighted shares and no anti-dilution flags. Cash burn eased to $23.6M YTD from $19.2M, yet a $115M stock offering swelled liquidity to $204M in cash and securities by June 30, 2025, with no debt. Positive Phase 2b CORAL results showed Haduvio slashing cough frequency by up to 60% in IPF patients, fueling Phase 3 plans. Cash extends runway through key milestones. Still, clinical delays could stretch funding needs.
IPO
Employees
Sector
Industry
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
INVA
Innoviva, Inc.
19.92-0.22
LQDA
Liquidia Corporation
35.26+1.07
NUVB
Nuvation Bio Inc.
8.66+0.15
TBPH
Theravance Biopharma, Inc.
17.53-0.24
TRAW
Traws Pharma, Inc.
2.20-0.04
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
UPB
Upstream Bio, Inc.
29.32+2.12
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75